Editorial Perspectives On Cell Line Development

  1. The Path To Producing An Insulin Biosimilar 7/17/2024

    I met with rBIO co-founder and president, Cameron Owen, as well as its CSO, Dr. Deenadayalan Bakthavatsalam, to learn about what it takes to develop an insulin biosimilar. They candidly told me about the company’s plan of execution, as well as how challenging it is to scale-up manufacturing to a commercial level (in the ballpark of several metric tons per year for insulin) — which is the company’s primary focus right now.

  2. Targeting The Gut–Brain Axis With Live Biotherapeutic Products 9/8/2023

    Treating seizures with bacteria — Bloom Science's CEO, Dr. Christopher Reyes, explains how his company aims to leverage the gut–brain axis using live biotherapeutic products (LBP).

  3. The “Liberation” Of Science Yields A New Class Of Biopharma Leadership 9/21/2022

    Purespring Therapeutics’ Richard Francis is among the dozens of big pharma executives who have defected to biopharma startups on the science, tech, and finance tides. “When I saw some of the acquisitions we were doing, it occurred to me that there’s no correlation between the places from which good science is emerging and a big R&D budget," he says.

  4. The Philogen Family Prepares For Market 9/6/2022

    In 1996, Prof. Dario Neri and his brothers Duccio and Giovanni founded the biopharma Philogen. Today, three of the company’s 17 clinical-stage programs are in phase 3 trials, seven in phase 2. Prof. Neri offered insight into the company’s academically rooted, metered approach on episode 103 of the Business of Biotech podcast.

  5. Why It's Computational Biology's Time To Shine 8/17/2022

    Astronomical biologic development costs, contracting capital markets, painfully long timelines, and an increasingly stingy regulatory environment are just a few of the reasons computational biology solutions are moving from the “luxury” column to the “survival” column for biopharmaceutical companies. 

  6. AAV Gene Therapy Takes On Kidney Disease 7/6/2022

    Built on the back of Prof. Moin Saleem’s two decades of cellular-level kidney research, Purespring Therapeutics is reimagining the treatment of kidney diseases that affect nearly a billion people worldwide. The company is preparing a first-of-its-kind AAV gene therapy candidate for the clinic. 

  7. The Coming Wave Of Radio(bio)pharmaceuticals 6/13/2022

    Convergent Therapeutics is bullish on the combination of radioisotopes and antibodies to direct radiation directly to cancer cells. As enabling technologies improve on previous failures, CEO, CMO, and co-founder Dr. Philip Kantoff is projecting a new wave of activity in the space among biopharmas big and small.

  8. Virtual Event: Overcome Platform Inefficiencies In mAb Manufacturing 6/7/2022

    Join multifaceted mAb manufacturing experts Gene Lee, CTO at AltruBio and Avril Vermunt, Sr. Director of Manufacturing Sciences & Technology at
    EQRx for a discussion on making mAbs more efficiently in the face of rising costs, growing complexity, and constricting cash runways. 

  9. IPSCs For Democratized Cell Therapy 6/7/2022

    Dr. Daniel Teper and his team at Cytovia Therapeutics have developed a unique combination of candidates designed to improve access to safe and affordable "off-the-shelf" cell therapies. Founded just four years ago, the company is preparing multiple clinical trials of IPSC-derived therapies, which Dr. Teper says lend to a consistent, scalable manufacturing process. 

  10. Will Anellovirus Vectors Solve Immunogenicity Challenges? 5/20/2022

    Ring Therapeutics is building a first-of-its-kind viral vector platform based on a commensal virus that flies under the immune system’s radar. If its odds-beating CEO is any indication of its success, the company just might beat the immunogenicity challenge.